Dexcom (DXCM) Current Deferred Revenue (2010 - 2025)

Dexcom (DXCM) has reported Current Deferred Revenue for 16 consecutive years, with $2.9 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Current Deferred Revenue fell 79.14% year-over-year to $2.9 million in Q3 2025; TTM through Sep 2025 was $2.9 million, a 79.14% decrease from a year earlier, with the FY2024 full-year figure at $8.0 million, down 56.52% from the prior year.
• Current Deferred Revenue was $2.9 million for Q3 2025 at Dexcom, down from $6.1 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $18.4 million in Q4 2023 and troughed at $1.8 million in Q2 2021.
• A 5-year average of $7.5 million and a median of $7.8 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 380.95% in 2022 and slumped 79.14% in 2025, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $2.1 million in 2021, then surged by 380.95% to $10.1 million in 2022, then surged by 82.18% to $18.4 million in 2023, then plunged by 56.52% to $8.0 million in 2024, then tumbled by 63.75% to $2.9 million in 2025.
• The last three Current Deferred Revenue figures came in at $2.9 million (Q3 2025), $6.1 million (Q2 2025), and $7.8 million (Q1 2025), per Business Quant data.